Survival from lung cancer remains poor in Scotland, UK. It is believed that comorbidity mayplay an important role in this. The goal of this study was to determine the value of a novel comorbidityscoring system (SCSS) and to compare it with the already established Charlson Comorbidity Index andthe modified Glasgow Prognostic Score (mGPS). We also wished to explore the relationship betweencomorbidity, mGPS and Performance Status (PS). In addition we investigated a number of standard pro-gnostic markers and demographics. This study aimed to determine which of these factors most accuratelypredicted survival.